Iron deficiency anemia (IDA) significantly impairs patients' work capacity and increases mortality, thereby constraining socioeconomic development. In most epidemiological surveys across both developing and developed countries, the overall mortality rate of IDA is generally underestimated19,20. The world health organization (WHO) explicitly recommends that researchers and clinicians thoroughly investigate the etiology of IDA and develop targeted therapeutic strategies, as timely intervention not only restores patients' health but also enhances national productivity21. IDA is induced by multiple complex factors, including insufficient iron intake, chronic blood loss, chronic diseases, malabsorption, hemolysis, or a combination of these2. Among these potential etiologies, whether H. pylori infection contributes to the development and progression of IDA remains controversial11,22,23. H. pylori infection is a highly prevalent global microbial disease, affecting over 50% of the global population; infection rates reach 70–90% in parts of Africa, Mexico, South America, and Central America24,25. This bacterium is a well-established major causative agent of digestive diseases such as peptic ulcers and gastric cancer26,27, and recent studies have also linked it to various extragastric conditions28,29,30. Current research evidence on the link between H. pylori infection and IDA is still insufficient. Accordingly, this study sought to elucidate the causal association between the two conditions.
A study first reported that H. pylori eradication exerts a beneficial therapeutic effect on refractory IDA, suggesting a potential link between H. pylori and IDA31. A large-scale U.S. population-based study enrolling 7,462 children, adolescents, and adults demonstrated that H. pylori infection is an independent risk factor for IDA, with infected individuals having a significantly increased risk of developing IDA (OR = 2.6, 95% CI: 1.5–4.6)32. Subsequent observational studies and meta-analyses have further validated this association: a previous meta-analysis integrating 15 observational investigations and 5 randomized controlled trials (RCTs) demonstrated a notable association between H. pylori infection and IDA, with a pooled OR of 2.22 (95% CI: 1.52–3.24, P < 0.0001). Moreover, following eradication therapy, patients exhibited a mean increase in hemoglobin of 4.06 g/L (95% CI: -2.57–10.69, P = 0.01) and a mean increase in serum ferritin of 9.47 μg/L (95% CI: -0.50–19.43, P < 0.0001)33. Study confirmed that approximately 60% of patients with H. pylori-associated IDA achieve significant anemia remission and marked elevations in key iron metabolic indices (e.g., serum ferritin, transferrin saturation) after H. pylori eradication33. These clinical findings collectively support a pathogenic role of H. pylori in IDA development, yet the underlying molecular mechanism bridging H. pylori OMP function and host iron depletion remains poorly elucidated.
Multiple well-recognized biological mechanisms underlie the initiation and exacerbation of IDA by H. pylori infection, with emerging molecular evidence highlighting the central role of outer membrane proteins (OMPs) in bacterial iron acquisition and the disruption of host iron homeostasis. The classic pathological pathway primarily involves gastric mucosal injury: H. pylori colonization induces damage to gastric epithelial cells, triggers chronic gastritis and mucosal atrophy, and suppresses gastric acid secretion. Gastric acid is indispensable for the release of dietary iron and subsequent intestinal absorption; thus, hypochlorhydria directly impairs iron bioavailability, leading to serum iron and transferrin saturation levels that meet the diagnostic criteria for IDA34. Concurrently, chronic inflammatory responses further downregulate the expression of duodenal iron transporters, limiting iron absorption, while exfoliation of damaged mucosal cells exacerbates intestinal iron loss—creating a dual iron-depleting effect characterized by reduced uptake and excessive consumption35,36. In addition to causing gastric mucosal damage, H. pylori competes directly with the host for iron acquisition through outer membrane proteins and other iron metabolism-regulatory proteins. Specifically, the bacterium expresses surface OMPs, such as lactoferrin-binding proteins and transferrin-binding proteins, which specifically recognize host iron carriers to sequester iron for bacterial proliferation. This process directly depletes systemic iron reserves, thereby triggering absolute iron deficiency35,37.
Additionally, infection-induced pro-inflammatory cytokines upregulate hepcidin expression, which mediates the internalization and degradation of intestinal iron transporters, blocks iron release from macrophages, and induces systemic iron sequestration—further exacerbating the anemic state38,39. Advancements in microbial molecular biology have clarified the functional characteristics of H. pylori iron metabolism-related proteins, particularly the OMP family, which provides a direct biological basis for interpreting the primary study findings40. Although canonical siderophores and their dedicated receptors have not been identified in H. pylori, the bacterium encodes a panel of key regulatory and transport proteins, including ferric uptake regulator (Fur), high-affinity ferrous iron transporter (FeoB), ferric citrate transporter (FecA), and non-heme iron-containing ferritin (Pfr)41. As a central transcriptional regulator, Fur senses ambient iron availability and modulates the expression of iron-responsive genes to maintain bacterial iron homeostasis42,43.
Notably, the OMP Frp family—comprising FrpB1, FrpB2, and FrpB3—possesses conserved β-barrel membrane structures and hemoglobin-binding motifs, with distinct expression patterns in response to different human iron sources (e.g., heme and hemoglobin)44. Under iron-limited conditions, FecA and Frp family OMPs are significantly upregulated to enhance bacterial iron-capturing capacity, whereas only minimal OMP expression is retained under iron-replete conditions to sustain basic metabolic demands45. These MR results, which reveal a causal association between H. pylori OMP antibody markers and IDA risk, align closely with this biological paradigm: elevated OMP-related immune responses reflect active H. pylori colonization and enhanced OMP-mediated iron sequestration, which directly disrupts host iron balance and increases IDA susceptibility.
Although the observed effect size of OMP antibodies on IDA is relatively modest (OR = 1.08), a small but statistically significant association is biologically and clinically meaningful in this context. As a chronic, cumulative metabolic disorder, IDA is often driven by long-term subtle perturbations in host iron homeostasis rather than strong acute triggers. Even a slight elevation in OMP antibody levels reflects persistent H. pylori colonization and sustained competitive iron acquisition at the gastric mucosal level, which can gradually exhaust systemic iron reserves and elevate long-term IDA risk. Such minor effect magnitudes are common in serological biomarker and chronic infectious disease-related analyses, and still carry valuable predictive etiological and public health implications, rather than being regarded as merely a trivial statistical finding.
Notably, the pathogenic association between H. pylori infection and IDA exhibits prominent geographical heterogeneity, which introduces inherent limitations to the generalizability of these findings, as they are derived exclusively from a European population. Such heterogeneity is largely attributed to interregional differences in H. pylori strain virulence, population dietary structure, and genetic background46. H. pylori isolates from East Asia are predominantly CagA-positive, mostly of the highly virulent EPIYA-D subtype, whereas Western strains have a higher proportion of low-virulence EPIYA-C subtypes47.
Dietary iron source patterns also modify disease susceptibility: plant-based iron, the major dietary iron source in East Asian populations, is highly dependent on gastric acid for absorption, rendering individuals more vulnerable to IDA when H. pylori infection suppresses acid secretion. In contrast, Western populations have a higher intake of animal-based iron, whose absorption is less susceptible to hypochlorhydria-mediated impairment. Additionally, inconsistent IDA diagnostic thresholds for serum ferritin and variable H. pylori detection methodologies across databases may introduce residual confounding. Methodologically, future studies could adopt multi-population two-sample MR designs, conduct stratified analyses by strain genotype and dietary pattern, and incorporate multi-omics data to validate the OMP-centered pathogenic pathway.
From a clinical perspective, H. pylori eradication offers distinct advantages over conventional single iron supplementation for the management of IDA. Specifically, combined H. pylori eradication and iron supplementation achieves superior therapeutic efficacy compared with iron monotherapy, particularly in idiopathic and refractory IDA cases46,48. Eradication therapy targets the fundamental etiology of H. pylori-related IDA, avoids gastrointestinal adverse events associated with long-term iron supplementation, and reduces long-term medical costs. Patients with persistent H. pylori infection also exhibit a poorer therapeutic response to iron supplementation alone, whereas prior bacterial eradication markedly improves iron repletion efficiency49. In East Asian regions with high H. pylori prevalence, routine H. pylori screening in IDA patients and standardized eradication for seropositive individuals hold substantial public health and clinical value. Collectively, this MR analysis of individuals of European ancestry confirms a robust causal association between circulating H. pylori OMP antibody levels and incident IDA risk, reinforcing the clinical rationale for incorporating H. pylori eradication into IDA therapeutic regimens.
Nevertheless, this study has limitations: it is constrained by population restriction, which limits cross-ethnic generalizability, and no significant correlations were observed between other H. pylori antibody subtypes and IDA risk. Large-scale multicenter studies encompassing diverse ethnic cohorts are therefore warranted to clarify the strain-specific pathogenic effects of H. pylori on IDA, validate the OMP-driven iron acquisition mechanism identified herein, and support the development of individualized prevention and targeted treatment strategies for patients with IDA.